1-20 of 32
Felix Y. Feng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Validation of a Digital Pathology–Based Multimodal Artificial Intelligence Biomarker in a Prospective, Real-World Prostate Cancer Cohort Treated with Prostatectomy

Anders Bjartell, Agnieszka Krzyzanowska, Vinnie Y.T. Liu, Meghan Tierney, Trevor J. Royce, Martin Sjöström, Marisol Macarena Palominos-Rivera, Emmalyn Chen, Alexandra Kraft, Andre Esteva, Felix Y. Feng
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (8): 1546–1553.
https://doi.org/10.1158/1078-0432.CCR-24-3656
Published: 14 April 2025
View articletitled, Validation of a Digital Pathology–Based Multimodal Artificial Intelligence Biomarker in a Prospective, Real-World Prostate Cancer Cohort Treated with Prostatectomy
Open the PDF for Validation of a Digital Pathology–Based Multimodal Artificial Intelligence Biomarker in a Prospective, Real-World Prostate Cancer Cohort Treated with Prostatectomy in another window
Includes: Supplementary data
Journal Articles

Abstract P007: A digital pathology multimodal artificial intelligence algorithm is associated with pro-metastatic genomic pathways in oligometastatic prostate cancer

Matthew P. Deek, Yang Song, Amol Shetty, Philip Sutera, Adrianna A. Mendes, Kim Van der Eecken, Emmalyn Chen, Timothy Showalter, Trevor J Royce, Tamara Todorovic, Huei-Chung Huang, Scott A. Houck, Rikiya Yamashita, Ana Ponce Kiess, Daniel Y. Song, Tamara Lotan, Andre Esteva, Felix Y. Feng, Piet Ost, Phuoc T. Tran
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2_Supplement): P007.
https://doi.org/10.1158/1557-3265.TARGETEDTHERAP-P007
Published: 26 January 2025
View articletitled, Abstract P007: A digital pathology multimodal artificial intelligence algorithm is associated with pro-metastatic genomic pathways in oligometastatic prostate cancer
Journal Articles

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors

Jonathan Chou, Troy M. Robinson, Emily A. Egusa, Roshan Lodha, Meng Zhang, Michelle Badura, Mane Mikayelyan, Henry M. Delavan, Jason Swinderman, Chris Wilson, Jun Zhu, Rajdeep Das, Minh Nguyen, Andrea Loehr, Tony Golsorkhi, Andrew Simmons, Wassim Abida, Arul M. Chinnaiyan, Michelle R. Arkin, Eric J. Small, David A. Quigley, Lixing Yang, Minkyu Kim, Alan Ashworth, Felix Y. Feng
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5445–5458.
https://doi.org/10.1158/1078-0432.CCR-23-3785
Published: 02 December 2024
View articletitled, Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Open the PDF for Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors in another window
Includes: Supplementary data
Journal Articles

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

Charles B. Nguyen, Melissa A. Reimers, Chamila Perera, Wassim Abida, Jonathan Chou, Felix Y. Feng, Emmanuel S. Antonarakis, Rana R. McKay, Russell K. Pachynski, Jingsong Zhang, Zachery R. Reichert, Phillip L. Palmbos, Megan E.V. Caram, Ulka N. Vaishampayan, Elisabeth I. Heath, Alexander C. Hopkins, Marcin P. Cieslik, Yi-Mi Wu, Dan R. Robinson, Veerabhadran Baladandayuthapani, Arul M. Chinnaiyan, Ajjai S. Alva
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3200–3210.
https://doi.org/10.1158/1078-0432.CCR-24-0400
Published: 01 August 2024
View articletitled, Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Open the PDF for Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial in another window
Includes: Supplementary data
Journal Articles

Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial

Axel Stenmark Tullberg, Martin Sjöström, Emma Niméus, Fredrika Killander, S. Laura Chang, Felix Y. Feng, Corey W. Speers, Lori J. Pierce, Anikó Kovács, Dan Lundstedt, Erik Holmberg, Per Karlsson
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1783–1793.
https://doi.org/10.1158/1078-0432.CCR-22-2746
Published: 01 May 2023
View articletitled, Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Open the PDF for Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial in another window
Includes: Supplementary data
Journal Articles

Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

Shalini Chopra, Kai Trepka, Sasank Sakhamuri, Alberto Carretero-González, Jun Zhu, Emily Egusa, Jie Zhou, Kevin Leung, Ning Zhao, Nima Hooshdaran, Felix Y. Feng, James A. Wells, Jonathan Chou, Michael J. Evans
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1232–1242.
https://doi.org/10.1158/1078-0432.CCR-22-1973
Published: 03 April 2023
View articletitled, Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Open the PDF for Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease

Ning Zhao, Shalini Chopra, Kai Trepka, Yung-Hua Wang, Sasank Sakhamuri, Nima Hooshdaran, Hyunjung Kim, Jie Zhou, Shion A. Lim, Kevin K. Leung, Emily A. Egusa, Jun Zhu, Li Zhang, Adam Foye, Renuka Sriram, Emily Chan, Youngho Seo, Felix Y. Feng, Eric J. Small, Jonathan Chou, James A. Wells, Rahul Aggarwal, Michael J. Evans
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3066–3075.
https://doi.org/10.1158/1078-0432.CCR-21-3858
Published: 15 July 2022
View articletitled, CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Open the PDF for CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease in another window
Includes: Supplementary data
Journal Articles

Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Carissa E. Chu, Martin Sjöström, Emily A. Egusa, Ewan A. Gibb, Michelle L. Badura, Jun Zhu, Vadim S. Koshkin, Bradley A. Stohr, Maxwell V. Meng, Raj S. Pruthi, Terence W. Friedlander, Yair Lotan, Peter C. Black, Sima P. Porten, Felix Y. Feng, Jonathan Chou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5123–5130.
https://doi.org/10.1158/1078-0432.CCR-20-4175
Published: 15 September 2021
View articletitled, Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Open the PDF for Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin in another window
Includes: Supplementary data
Journal Articles

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

Dae-Hwan Kim, Duanchen Sun, William K. Storck, Katherine Welker Leng, Chelsea Jenkins, Daniel J. Coleman, David Sampson, Xiangnan Guan, Anbarasu Kumaraswamy, Eva S. Rodansky, Joshua A. Urrutia, Jacob A. Schwartzman, Chao Zhang, Himisha Beltran, Mark P. Labrecque, Colm Morrissey, Jared M. Lucas, Ilsa M. Coleman, Peter S. Nelson, Eva Corey, Samuel K. Handelman, Jonathan Z. Sexton, Rahul Aggarwal, Wassim Abida, Felix Y. Feng, Eric J. Small, Daniel E. Spratt, Armand Bankhead, III, Arvind Rao, Emily M. Gesner, Sarah Attwell, Sanjay Lakhotia, Eric Campeau, Joel A. Yates, Zheng Xia, Joshi J. Alumkal
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4923–4936.
https://doi.org/10.1158/1078-0432.CCR-20-4968
Published: 01 September 2021
View articletitled, BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Open the PDF for BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program in another window
Includes: Supplementary data
Journal Articles

Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease

Matthew R. Smith, Shibu Thomas, Michael Gormley, Simon Chowdhury, David Olmos, Stéphane Oudard, Felix Y. Feng, Yashoda Rajpurohit, Karen Urtishak, Deborah S. Ricci, Brendan Rooney, Angela Lopez-Gitlitz, Margaret Yu, Alexander W. Wyatt, Mark Li, Gerhardt Attard, Eric J. Small
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4539–4548.
https://doi.org/10.1158/1078-0432.CCR-21-0358
Published: 15 August 2021
View articletitled, Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Open the PDF for Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease in another window
Includes: Supplementary data
Journal Articles

Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

Sinan Wang, Jun Li, Jun Hua, Yang Su, Denis R. Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony L. Huynh, Ning Zhao, Yung-hua Wang, Yangjie Huang, Fujun Qin, Sui Shen, Daniel Gioeli, Robert Dreicer, Renuka Sriram, Emily A. Egusa, Jonathan Chou, Felix Y. Feng, Rahul Aggarwal, Michael J. Evans, Youngho Seo, Bin Liu, Robert R. Flavell, Jiang He
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1305–1315.
https://doi.org/10.1158/1078-0432.CCR-20-3310
Published: 01 March 2021
View articletitled, Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET
Open the PDF for Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET in another window
Includes: Supplementary data
Journal Articles

Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial

Axel Stenmark Tullberg, Henri A.J. Puttonen, Martin Sjöström, Erik Holmberg, S. Laura Chang, Felix Y. Feng, Corey Speers, Lori J. Pierce, Dan Lundstedt, Fredrika Killander, Emma Niméus, Anikó Kovács, Per Karlsson
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (3): 749–758.
https://doi.org/10.1158/1078-0432.CCR-20-3299
Published: 01 February 2021
View articletitled, Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial
Open the PDF for Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial in another window
Includes: Supplementary data
Journal Articles

Autoantibody Landscape in Patients with Advanced Prostate Cancer

William S. Chen, Winston A. Haynes, Rebecca Waitz, Kathy Kamath, Agustin Vega-Crespo, Raunak Shrestha, Minlu Zhang, Adam Foye, Ignacio Baselga Carretero, Ivan Perez Garcilazo, Meng Zhang, Shuang G. Zhao, Martin Sjöström, David A. Quigley, Jonathan Chou, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, Primo Lara, Kim N. Chi, Robert E. Reiter, Joshi J. Alumkal, Alan Ashworth, Rahul Aggarwal, Eric J. Small, Patrick S. Daugherty, Antoni Ribas, David Y. Oh, John C. Shon, Felix Y. Feng
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6204–6214.
https://doi.org/10.1158/1078-0432.CCR-20-1966
Published: 01 December 2020
View articletitled, Autoantibody Landscape in Patients with Advanced Prostate Cancer
Open the PDF for Autoantibody Landscape in Patients with Advanced Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Rahul R. Aggarwal, Michael T. Schweizer, David M. Nanus, Allan J. Pantuck, Elisabeth I. Heath, Eric Campeau, Sarah Attwell, Karen Norek, Margo Snyder, Lisa Bauman, Sanjay Lakhotia, Felix Y. Feng, Eric J. Small, Wassim Abida, Joshi J. Alumkal
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5338–5347.
https://doi.org/10.1158/1078-0432.CCR-20-1707
Published: 15 October 2020
View articletitled, A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Open the PDF for A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer

Xiangnan Guan, Duanchen Sun, Eric Lu, Joshua A. Urrutia, Robert Evan Reiter, Matthew Rettig, Christopher P. Evans, Primo Lara, Jr, Martin Gleave, Tomasz M. Beer, George V. Thomas, Jiaoti Huang, Rahul R. Aggarwal, David A. Quigley, Adam Foye, William S. Chen, Jack Youngren, Alana S. Weinstein, Joshua M. Stuart, Felix Y. Feng, Eric J. Small, Zheng Xia, Joshi J. Alumkal
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4616–4624.
https://doi.org/10.1158/1078-0432.CCR-19-2303
Published: 01 September 2020
View articletitled, Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Wassim Abida, David Campbell, Akash Patnaik, Jeremy D. Shapiro, Brieuc Sautois, Nicholas J. Vogelzang, Eric G. Voog, Alan H. Bryce, Ray McDermott, Francesco Ricci, Julie Rowe, Jingsong Zhang, Josep Maria Piulats, Karim Fizazi, Axel S. Merseburger, Celestia S. Higano, Laurence E. Krieger, Charles J. Ryan, Felix Y. Feng, Andrew D. Simmons, Andrea Loehr, Darrin Despain, Melanie Dowson, Foad Green, Simon P. Watkins, Tony Golsorkhi, Simon Chowdhury
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2487–2496.
https://doi.org/10.1158/1078-0432.CCR-20-0394
Published: 01 June 2020
View articletitled, Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Open the PDF for Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study in another window
Includes: Supplementary data
Journal Articles

Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

Yingming Li, Rendong Yang, Christine M. Henzler, Yeung Ho, Courtney Passow, Benjamin Auch, Suzanne Carreira, Daniel Nava Rodrigues, Claudia Bertan, Tae Hyun Hwang, David A. Quigley, Ha X. Dang, Colm Morrissey, Michael Fraser, Stephen R. Plymate, Christopher A. Maher, Felix Y. Feng, Johann S. de Bono, Scott M. Dehm
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1965–1976.
https://doi.org/10.1158/1078-0432.CCR-19-3023
Published: 15 April 2020
View articletitled, Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Open the PDF for Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy

Martin Sjöström, S. Laura Chang, Nick Fishbane, Elai Davicioni, Linda Hartman, Erik Holmberg, Felix Y. Feng, Corey W. Speers, Lori J. Pierce, Per Malmström, Mårten Fernö, Per Karlsson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 171–182.
https://doi.org/10.1158/1078-0432.CCR-19-1038
Published: 03 January 2020
View articletitled, Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy
Open the PDF for Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy in another window
Includes: Supplementary data
Journal Articles

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer

Daniel E. Spratt, Mohammed Alshalalfa, Nick Fishbane, Adam B. Weiner, Rohit Mehra, Brandon A. Mahal, Jonathan Lehrer, Yang Liu, Shuang G. Zhao, Corey Speers, Todd M. Morgan, Adam P. Dicker, Stephen J. Freedland, R. Jeffery Karnes, Sheila Weinmann, Elai Davicioni, Ashley E. Ross, Robert B. Den, Paul L. Nguyen, Felix Y. Feng, Tamara L. Lotan, Arul M. Chinnaiyan, Edward M. Schaeffer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6721–6730.
https://doi.org/10.1158/1078-0432.CCR-19-1587
Published: 15 November 2019
View articletitled, Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Open the PDF for Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

Emanuela Dylgjeri, Christopher McNair, Jonathan F. Goodwin, Heather K. Raymon, Peter A. McCue, Ayesha A. Shafi, Benjamin E. Leiby, Renée de Leeuw, Vishal Kothari, Jennifer J. McCann, Amy C. Mandigo, Saswati N. Chand, Matthew J. Schiewer, Lucas J. Brand, Irina Vasilevskaya, Nicolas Gordon, Talya S. Laufer, Leonard G. Gomella, Costas D. Lallas, Edouard J. Trabulsi, Felix Y. Feng, Ellen H. Filvaroff, Kristin Hege, Dana Rathkopf, Karen E. Knudsen
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5623–5637.
https://doi.org/10.1158/1078-0432.CCR-18-2207
Published: 13 September 2019
View articletitled, Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies
Open the PDF for Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies in another window
Includes: Supplementary data